ILMN
Illumina, Inc.NASDAQHealthcareAs of 2026-04-06
Valuation
View DetailsP/E (TTM)
22.91
PEG
0.14
P/B
7.16
P/S
4.49
EV/EBITDA
14.15
DCF Value
$-59.86
FCF Yield
4.8%
Div Yield
0.0%
Margins & Returns
Gross Margin
66.5%
Operating Margin
19.9%
Net Margin
19.6%
ROE
34.9%
ROA
16.0%
ROIC
12.0%
Financials
View All| Period | Revenue | Net Income | EPS |
|---|---|---|---|
| Q4 2025 | $1.16B | $334.0M | $2.16 |
| FY 2025 | $4.34B | $850.0M | $5.44 |
| Q3 2025 | $1.08B | $150.0M | $0.97 |
| Q2 2025 | $1.06B | $235.0M | $1.49 |
Analyst Ratings
View AllTrading Activity
Insider Trades
View AllCompany Info
Sector
Healthcare
Industry
—
Country
US
Exchange
NASDAQ
Beta
1.49
Illumina, Inc. provides sequencing and array-based solutions for genetic and genomic analysis. Its products and services serve customers in a range of markets enabling the adoption of genomic solutions in research and clinical settings for applications in the life sciences, oncology, reproductive health, agriculture, and other emerging segments. The company provides instruments and consumables used in genetic analysis; and genotyping and sequencing services, instrument service contracts, and development and licensing agreements, as well as cancer detection testing services. Its customers include genomic research centers, academic institutions, government laboratories, and hospitals, as well as pharmaceutical, biotechnology, commercial molecular diagnostic laboratories, and consumer genomics companies. The company markets and distributes its products directly to customers in North America, Europe, Latin America, and the Asia-Pacific region, as well as sells through life-science distributors in various markets within Europe, the Asia-Pacific region, Latin America, the Middle East, and Africa. The company was incorporated in 1998 and is based in San Diego, California.